| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-08-20 | PharmaMar (Spain) Specialised Therapeutics Australia (Australia) | Aplidin® (plitidepsin) | multiple myeloma, T cell lymphoma | licensing commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-08-20 | Sygnis (Germany) Nanodigmbio (China) | Sygnis\' portfolio including TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA | Technology - Services | Distribution agreement | ||
| 2015-08-20 | Leo Pharma (Denmark) SkinVision (The Netherlands) | SkinVision App | melanoma | collaboration |
Technology - Services - Cancer - Oncology - Dermatological diseases | Collaboration agreement |
| 2015-08-20 | Axelar (Sweden) Cadila Pharmaceuticals (Sweden) | AXL1717 (picropodophyllin) | non-small cell lung cancer (NSCLC) | development |
Cancer - Oncology | Development agreement |
| 2015-08-19 | Abbvie (USA - IL) United Therapeutics (USA - MD) | Rare Pediatric Disease Priority Review Voucher (PPRV) | commercialisation | Rare diseases | Commercialisation agreement | |
| 2015-08-19 | Lundbeck (Denmark) | restructuring |
Restructuring | |||
| 2015-08-19 | SELLAS Life Sciences (Switzerland) | nomination |
Cancer - Oncology - CNS diseases | Nomination | ||
| 2015-08-18 | Pieris (Germany) | nomination |
Nomination | |||
| 2015-08-18 | OncoCyte Corporation, BioTime, Inc.\'s Subsidiary (USA - CA) The Wistar Institute (USA - PA) | blood-based test for the early detection of lung cancer | lung cancer | collaboration development |
Cancer - Oncology - Diagnostic | Development agreement |
| 2015-08-18 | Biogen (USA - MA) the ALS Association (USA) Columbia University Medical Center (USA - NY) | “Genomic Translation for ALS Clinical care” (GTAC) | amyotrophic lateral sclerosis | collaboration |
Neurodegenerative diseases - Rare diseases | Collaboration agreement |
| 2015-08-18 | Helix (USA - CA) Mayo Clinic (USA - MN) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2015-08-18 | Helix (USA - CA) Mayo Clinic (USA - MN) Laboratory Corporation of America® Holdings (LabCorp) (USA - NC) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2015-08-18 | MDxHealth (Belgium) University Erasmus Medical Center (Belgium) | bladder cancer DNA methylation biomarkers for both laboratory developed tests as well as in vitro diagnostic (IVD) products | bladder cancer | licensing |
Cancer - Oncology - Diagnostic | Licensing agreement |
| 2015-08-18 | Therametrics (Switzerland) Grünenthal (Germany) | DRR2.0 System Technology | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-08-17 | Aveo Oncology (USA - MA) Novartis (Switzerland) | AV-380 and related antibodies | cancer cachexia | licensing development manufacturing production commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-08-17 | VolitionRx (Singapore - Belgium) | nomination |
Diagnostic | Nomination | ||
| 2015-08-17 | ITeos Therapeutics (Belgium) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-08-14 | Prima BioMed (Australia) Novartis (Switzerland) | IMP701 - LAG-3 antibody | milestone |
Cancer - Oncology | Milestone | |
| 2015-08-13 | Merck&Co (USA - NJ) MD Anderson Cancer Center (USA - TX) | Keytruda® (pembrolizumab) | solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-08-12 | Heidelberg Pharma (Germany) Roche (Switzerland) | novel Antibody Targeted Amanitin Conjugates (ATACs) | termination of an agreement |
Cancer - Oncology | Termination of an agreement |
